StonvexLoading…
StonvexStonvexStonvexCore line items from ACCS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $5.62M | $5.33M | $22.62M | $16.82M | $11.10M |
Operating Income | Not available | $-718.00K | $-1.87M | $-1.11M | $-926.00K |
Net Income | Not available | $-611.00K | $4.29M | $4.87M | $-475.00K |
EPS (Diluted) | $0.17 | $-0.16 | $1.11 | $1.26 | $1.28 |
Total Assets | Not available | $41.59M | $41.99M | $44.05M | $45.55M |
Total Liabilities | Not available | $11.65M | $11.65M | $13.26M | $14.87M |
Cash & Equivalents | Not available | $3.49M | $3.02M | $3.26M | $4.11M |
Free Cash Flow OCF − CapEx | Not available | $862.00K | $538.00K | $280.00K | $870.00K |
Shares Outstanding | Not available | 3.88M | 3.85M | 3.87M | 3.87M |